Skip to main content
SpringerLink
Log in

Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Erythropoiesis-stimulating agents (ESAs) have become a hallmark of anaemia therapy in patients with chronic kidney disease (CKD). Although different ESAs are available for the treatment of renal anaemia, each nephrologist should select a single ESA for an individual patient. Epoetin alfa and epoetin beta have been used 1–3 times weekly but extended-interval dosing up to every 4 weeks is also effective in a substantial majority of CKD patients. However, the epoetin dose necessary to achieve or maintain target haemoglobin (Hb) levels increases substantially as the dosing interval increases. Subcutaneous administration of short-acting ESAs is more effective than the intravenous route of administration. Darbepoetin alfa and the continuous erythropoietin receptor activator (CERA) have been developed as a treatment for anaemia with extended administration intervals (every 2 weeks and every 4 weeks, respectively). Dose requirements for these long-acting ESAs are independent of the route of administration. Patents of short-acting ESAs have expired, which has opened the field for biosimilars. Epoetin biosimilars approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) have been shown to have a comparable efficacy and safety profile to their originators. An alarming increase in pure red cell aplasia (PRCA) in Thailand with follow-on epoetins manufactured in Asia (but also those manufactured in Latin America) indicates that stringent country-specific approval and pharmacovigilance protocols for ESAs manufactured in non-North American and non-EU European countries are urgently needed. Two PRCA cases occurring with subcutaneous HX575 (one certain, one likely) indicate that chances of inducing a more immunogenic product are unpredictable, even with a biosimilar epoetin approved under the EMA biosimilar approval pathway. Phase III clinical trials with peginesatide, a pegylated synthetic peptide-based ESA without any homology to erythropoietin raised safety concerns in non-dialysis CKD patients but not in dialysis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43:649–59.

    PubMed  CAS  Google Scholar 

  2. Deicher R, Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64:499–509.

    PubMed  CAS  Google Scholar 

  3. Locatelli F, Covic A, Eckardt KU, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348–54.

    PubMed  Google Scholar 

  4. Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:935–7.

    Google Scholar 

  5. Piccolo AM, Malagoli A, Komninos G, et al. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol. 2002;15:565–74.

    Google Scholar 

  6. Provenzano R, Bhaduri S, Singh AK, et al. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease. The PROMPT study. Clin Nephrol. 2005;64:113–23.

    PubMed  CAS  Google Scholar 

  7. Lim VS, Kirchner PT, Fangman J, et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis. 1989;14:496–506.

    PubMed  CAS  Google Scholar 

  8. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004;61:392–405.

    PubMed  CAS  Google Scholar 

  9. Benz R, Schmidt R, Kelly K, et al. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:215–21.

    PubMed  CAS  Google Scholar 

  10. Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005;20:2146–52.

    PubMed  CAS  Google Scholar 

  11. Pergola P, Gartenberg G, Fu M, et al. A randomized controlled study of weekly and every-2-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol. 2009;4:1731–40.

    PubMed  CAS  Google Scholar 

  12. Pergola PE, Gartenberg G, Fu M, et al. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol. 2010;5:598–606.

    PubMed  CAS  Google Scholar 

  13. Gobin J, Cernii A. Mc Lean R et al. Conversion from epoetin alfa to darbepoetin alfa for management of anemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig. 2011;31:113–20.

    PubMed  Google Scholar 

  14. Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update of the European experiences. Am J Hematol. 2010;85:771–80.

    PubMed  Google Scholar 

  15. European Public Assessment Report (EPAR). Eporatio® [online]. Available from URL: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001033/human_med_001204.jsp [Accessed 2012 Nov 26].

  16. Gertz B, Kes P, Essaian A, et al. Epoetin alfa: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin. 2012;28:1101–10.

    PubMed  CAS  Google Scholar 

  17. Sörgel F, Thyroff-Frieslinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.

    PubMed  Google Scholar 

  18. Sörgel F, Thyroff-Friesinger U, Vetter A, et al. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol. 2009;47:391–401.

    Google Scholar 

  19. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72:380–90.

    PubMed  CAS  Google Scholar 

  20. Hörl WH, Locatelli F, Haag-Weber M, et al. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol. 2012;78:24–32.

    PubMed  Google Scholar 

  21. Haag-Weber M, Eckardt K-U, Hörl WH, et al. Safety, immunogenicity of subcutaneous biosimilar epoetin alfa (HX575) in non-dialysis patients with renal anaemia: a multi-centre, randomised, double-blind study. Clin Nephrol. 2012;77:8–17.

    PubMed  CAS  Google Scholar 

  22. Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs. 2011;11:61–75.

    Google Scholar 

  23. Macdougall IC, Roger S, De Francisco A, et al. Antibody-mediated pure red cell aplasia in patients receiving ESA therapy: new insights. Kidney Int. 2012;81:727–32.

    PubMed  CAS  Google Scholar 

  24. Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packing as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.

    PubMed  CAS  Google Scholar 

  25. Van Beers MM, Jiskoot W, Schellekens H. On the role of aggravates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res. 2010;30:767–75.

    PubMed  Google Scholar 

  26. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3:123–30.

    PubMed  CAS  Google Scholar 

  27. Ryan MH, Heavner GA, Brigham-Burke M, et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunpharmacol. 2006;6:647–55.

    CAS  Google Scholar 

  28. Jiang Y, Nashed-Samuel Y, Li C, et al. Tungsten-induced protein aggregation: solution behaviour. J Pharm Sci. 2009;98:4765–70.

    Google Scholar 

  29. Bee JS, Nelson SA, Freund E, et al. Precipitation of a monoclonal antibody to soluble tungsten. J Pharm Sci. 2009;98:3290–301.

    PubMed  CAS  Google Scholar 

  30. Liu W, Swift R, Torraca G, et al. Root cause analysis of tungsten-induced protein aggregation in pure-filled syringes. PDA J Pharm Sci Tech. 2010;64:11–9.

    CAS  Google Scholar 

  31. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625–37.

    PubMed  CAS  Google Scholar 

  32. Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–15.

    PubMed  CAS  Google Scholar 

  33. Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27:105–17.

    PubMed  CAS  Google Scholar 

  34. Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: a single-dialysis center experience. Clin Nephrol. 2011;75:59–62.

    PubMed  CAS  Google Scholar 

  35. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28:386–9.

    PubMed  CAS  Google Scholar 

  36. Hörbrand F, Bramlage P, Fischaleck J, et al. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. Epub 2012 Oct 2.

  37. Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf. 2012;11:819–40.

    PubMed  CAS  Google Scholar 

  38. Goldsmith D. 2009: a requiem for rHuEPOs: but should we nail down the coffin in 2010? Clin J Am Soc Nephrol. 2010;5:929–35.

    Google Scholar 

  39. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008;74:1617–22.

    PubMed  Google Scholar 

  40. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol. 2008;3:174–8.

    PubMed  Google Scholar 

  41. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25:954–62.

    PubMed  CAS  Google Scholar 

  42. Praditpornsilpa K, Tiranathanagul K, Kupawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88–92.

    PubMed  CAS  Google Scholar 

  43. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis. 2009;16:117–30.

    PubMed  Google Scholar 

  44. Perez-Oliva JF, Casanova-Gonzales M, Garcia-Garcia I, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel randomized, double blind study. BMC Nephrol. 2005;6:1–11.

    Google Scholar 

  45. Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-equimolar dosis maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant. 2008;23:301–8.

    PubMed  CAS  Google Scholar 

  46. Tanakitcharu P, Siriwiwatanakul N. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. J Med Assoc Thai. 2007;90:2574–86.

    Google Scholar 

  47. Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15(Suppl. 3):14–8.

    PubMed  Google Scholar 

  48. Park SS, Park J, Ko J, et al. Biochemical assessment of erythropoietin products from Asia versus US epoetin alfa manufactured by Amgen. J Pharm Sci. 2008;98:1688–99.

    Google Scholar 

  49. Schmidt CA, Ramos AS, da Silva JEP, et al. Availiaco da atividade e caracterizacão de erithropoietin a humana recombinante em produtos farmacéuticos. Arq Bras Endocrinol Metabol. 2003;47:183–9.

    Google Scholar 

  50. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;3:43–7.

    Google Scholar 

  51. Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: you can’t fool mother nature. Kidney Int. 2011;80:11–3.

    PubMed  CAS  Google Scholar 

  52. Schellekens H. Follow-on biologics challenges of the next generation. Nephrol Dial Transplant 2005; 20 Suppl. 4: iv31–6.

    Google Scholar 

  53. Roger SD, Goldsmith D. Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther. 2008;33:459–64.

    PubMed  CAS  Google Scholar 

  54. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010;10:1–8.

    Google Scholar 

  55. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl. 1):3–10.

    PubMed  CAS  Google Scholar 

  56. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–5.

    PubMed  CAS  Google Scholar 

  57. Doshi S, Chow A, Pérez Ruixo JJ. Exposure-response modelling of darbepoetin alfa in anemic patiens with chronic kidney disease not receiving dialysis. J Clin Pharmacol. 2010;50:755–905.

    Google Scholar 

  58. Aarup M, Bryndum J, Dieperink H, et al. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant. 2006;21:1312–6.

    PubMed  CAS  Google Scholar 

  59. Sharma A, Yee J, Gandra SR, et al. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin. 2010;26:2679–87.

    PubMed  CAS  Google Scholar 

  60. Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm. 2009;15:741–50.

    PubMed  Google Scholar 

  61. Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant. 2003;18:362–9.

    PubMed  CAS  Google Scholar 

  62. Mann J, Kessler M, Villa G, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol. 2007;67:140–8.

    PubMed  CAS  Google Scholar 

  63. Tolman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005;16:1463–70.

    PubMed  Google Scholar 

  64. Weiss LG, Clyne N, Divino FJ, et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled mulitcenter trial. Swedish Study Group. Nephrol Dial Transplant. 2000;15:2014–9.

    PubMed  CAS  Google Scholar 

  65. Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002;40:119–25.

    PubMed  CAS  Google Scholar 

  66. Lafeuille MH, Bailey RH, Vekeman F, et al. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease. Consult Pharm. 2010;25:493–500.

    PubMed  Google Scholar 

  67. Rottembourg JB, Bridges I, Pronai W, et al. An observational study of the effectiveness of darbepoetin alpha administered to dialysis patients once every 2 weeks for 12 months. Clin Nephrol. 2011;75:242–50.

    PubMed  CAS  Google Scholar 

  68. Feriani M, De Meester JMJ, McMahon LP, et al. Extended dosing of darbepoetin alfa in peritoneal dialysis patients. BMC Nephrol. 2011;12:13.

    PubMed  CAS  Google Scholar 

  69. Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains haemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327–54.

    PubMed  CAS  Google Scholar 

  70. Aranesp Summary of Product Characteristics. 2006 [online]. Available from URL: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/human_med_000651.jsp&mid=WC0b01ac058001d124 [Accessed 2012 Nov 26].

  71. Galle J-C, Claes K, Kiss I, et al. An observational color study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant. 2012;27:2303–11.

    PubMed  CAS  Google Scholar 

  72. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.

    PubMed  CAS  Google Scholar 

  73. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.

    PubMed  Google Scholar 

  74. Lim WH, Boudville N, Pellicano S, et al. Patients’ perceptions of subcutaneous delivery of darbepoetin alfa by autoinjector prefilled pen versus prefilled syringe: a randomized, crossover study. Clin Ther. 2012;34:1948–53.

    PubMed  CAS  Google Scholar 

  75. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–5.

    PubMed  CAS  Google Scholar 

  76. Jarsch M, Brandt M, Lanzendörfer M, et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81:63–9.

    PubMed  CAS  Google Scholar 

  77. Koch M, Henrich D, Faust J, et al. Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial. Clin Nephrol. 2012;78:189–97.

    PubMed  CAS  Google Scholar 

  78. Levin NW, Fishbane S, Valdés Cañedo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–21.

    PubMed  CAS  Google Scholar 

  79. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–46.

    PubMed  CAS  Google Scholar 

  80. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007;50:989–1000.

    PubMed  CAS  Google Scholar 

  81. Spinowitz B, Coyne DW, Lok CE, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28:280–9.

    PubMed  CAS  Google Scholar 

  82. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–47.

    PubMed  Google Scholar 

  83. Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26:3980–6.

    PubMed  CAS  Google Scholar 

  84. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654–61.

    PubMed  CAS  Google Scholar 

  85. Kessler M, Martinez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. Hemodial Int. 2010;14:233–9.

    PubMed  Google Scholar 

  86. Mann JF, de Francisco A, Nassar G, et al. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76:9–15.

    PubMed  CAS  Google Scholar 

  87. Heidenreich S, Leistikow F, Zinn S, et al. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre. SUPRA study. Clin Drug Investig. 2012;32:99–110.

    PubMed  CAS  Google Scholar 

  88. Leypolt JK, Loghman-Adham M, Jordan P, et al. Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations. Hemodial Int. 2012;16:20–30.

    Google Scholar 

  89. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009–17.

    PubMed  CAS  Google Scholar 

  90. Minutolo R, Zamboli P, Chiodini P, et al. Conversion of darbepoetin to low doses of CERA maintains haemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif. 2010;30:186–94.

    PubMed  CAS  Google Scholar 

  91. Cano F, Alarcon C, Azocar M, et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol. 2011;26:1303–10.

    PubMed  Google Scholar 

  92. Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73:94–103.

    PubMed  CAS  Google Scholar 

  93. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.

    PubMed  CAS  Google Scholar 

  94. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458–64.

    PubMed  CAS  Google Scholar 

  95. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34:1303–11.

    PubMed  CAS  Google Scholar 

  96. Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol. 2006;26:313–8.

    PubMed  Google Scholar 

  97. Omontys® (peginesatide) injection [prescribing information]. Palo Alto (CA): Affymax Inc, 2012.

  98. Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6:2579–86.

    PubMed  CAS  Google Scholar 

  99. Besarab A, Zeig SN, Martin ER, et al. An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. Nephrology. 2012;13:95.

    PubMed  CAS  Google Scholar 

  100. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59:444–51.

    PubMed  Google Scholar 

  101. Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med. 2012;3:25–31.

    PubMed  CAS  Google Scholar 

  102. Woodburn KW, Schatz PJ, Fong KL, et al. Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys. Drug Chem Toxicol. 2008;31:229–44.

    PubMed  CAS  Google Scholar 

  103. Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol. 2007;35:1201–8.

    PubMed  CAS  Google Scholar 

  104. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.

    PubMed  CAS  Google Scholar 

  105. Louët S. Lessons from Eprex for biogeneric firms. Nat Biotechnol. 2003;21:956–7.

    PubMed  Google Scholar 

  106. Yang J. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J Nephrol. 2005;18:102–5.

    PubMed  Google Scholar 

  107. Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant. 2006;21:2963–5.

    PubMed  CAS  Google Scholar 

  108. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant. 2007;22:1462–4.

    PubMed  Google Scholar 

  109. Attaf DC, Torres PA. Not all new recombinant human erythropoietins are biosimilars [letter]. Kidney Int. 2009;74:441.

    Google Scholar 

  110. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents: time for a reevaluation. N Engl J Med. 2010;362:189–92.

    PubMed  CAS  Google Scholar 

  111. Szczech LA. Chronic kidney disease anemia management: what should be done? Blood Purif. 2011;31:186–8.

    PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to conduct this study or prepare this manuscript. Professor Walter H. Hörl has associations with the following companies: Amgen (speakers’ bureau), Sandoz (consultant), Hexal (consultant, speakers’ bureau), Fresenius (speakers’ bureau, research support), Vifor (consultant, speakers’ bureau, grant/research support), Medice (speakers’ bureau), Abbott (speakers’ bureau) and Takeda (consultant).

Author information

Authors and Affiliations

  1. Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Walter H. Hörl

Authors
  1. Walter H. Hörl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter H. Hörl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hörl, W.H. Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease. Drugs 73, 117–130 (2013). https://doi.org/10.1007/s40265-012-0002-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-012-0002-2

Keywords

Search

Navigation